Yale’s saliva-based COVID-19 test receives FDA authorization for emergency use

Coronavirus

NEW HAVEN, Conn. (WTNH) — The Yale School of Public Health’s saliva-based coronavirus test has been authorized for emergency use by the U.S. Food and Drug Administration (FDA).

The new test is now available for emergency use in diagnostic laboratories nationwide, and will possibly be available for international use in the coming weeks, according to Yale.

Yale says the SalivaDirect test is less expensive and less invasive than the nasal swab test and has produced results similar to the nasal swab test. Researchers expect that labs will charge around $10 per sample.

Yale also relies on multiple vendors for reagents and instruments to gain flexibility in any possible supply chain issues.

Researchers see this test as a ‘game-changer’ in COVID-19 diagnostics, and, according to Yale postdoctoral fellow, Chantal Vogels, a “huge step forward to making testing more accessible.”

Yale is partnering with The Jackson Laboratory for Genomic Medicine in Farmington to explore how to implement the saliva-based test for a broader audience.

Right now, this test is primarily used to test asymptomatic people.

The SalivaDirect test is currently being tested on players and staff from the National Basketball Association while the playing season continues in Orlando.

For more information, click here.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

New Haven

Yale Medicine doctor weighs in on importance of flu shots this season

News /

Waterbury ambulance crew, mother discuss opioid crisis on the streets

News /

West Haven state lawmaker expected to resign his elected office amid an FBI probe

News /

Communities urging federal government to take action on the Kinneytown Dam in Seymour

News /

Waterbury police arrest 10 women during prostitution sting

News /

Reopening celebration held following upgrades at Meriden Markham Airport

News /
More New Haven

Trending Stories

Don't Miss

More Don't Miss